• Markets
  • icon
  • Companies
SPL · ASX

Starpharma Holdings Limited (ASX:SPL)

AU$0.14

 0.0 (0.0%)
ASX:Live
05/12/2023 04:10:44 PM
HALO Ords GROWTH AUS All-Consensus All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

SPL Overview

SPL Health Scores

Short Term

Mean Revision

Trend

Event

Halo Model

MQV

GARP

MQV Small

Valuation

Value

Consensus

Momentum

Price

Earnings

Growth

Earnings

Dividends

Quality

Capital Efficiency

Balance Sheet

About SPL

Telephone

Address

Description

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The firm's programs include: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

SPL Price Chart

Key Stats

Market Cap

AU$57.64M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.12 - 0.7

Trade Value (12mth)

AU$34,017.00

1 week

0%

1 month

-3.57%

YTD

-74.53%

1 year

-75.23%

All time high

2.52

Key Fundamentals

EPS 3 yr Growth

-3.000%

EBITDA Margin

-798.90%

Operating Cashflow

-$14m

Free Cash Flow Return

-29.00%

ROIC

-33.50%

Interest Coverage

N/A

Quick Ratio

3.10

Other Data

Shares on Issue (Fully Dilluted)

410m

HALO Sector

Next Company Report Date

21-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.60

SPL Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 22

Change in Director's Interest Notice - J Fairley

×

Change in Director's Interest Notice - J Fairley

31 October 22

Change in Director's Interest Notice - R Thomas

×

Change in Director's Interest Notice - R Thomas

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 July 23

Partnered Program Update

×

Partnered Program Update

31 January 23

Dr Russell Basser appointed as non-executive director

×

Dr Russell Basser appointed as non-executive director

31 August 11

Starpharma presents at Macquarie investor event

×

Starpharma presents at Macquarie investor event

30 September 22

2022 Annual General Meeting Date

×

2022 Annual General Meeting Date

30 September 20

Investor Presentation

×

Investor Presentation

30 September 09

Annual Report to shareholders

×

Annual Report to shareholders

30 November 22

Retirement of non-executive Director

×

Retirement of non-executive Director

30 November 21

AGM Chairman address and CEO presentation

×

AGM Chairman address and CEO presentation

30 November 12

AGM Chair address and CEO presentation

×

AGM Chair address and CEO presentation

30 June 22

VIRALEZE relaunched by LloydsPharmacy in the UK

×

VIRALEZE relaunched by LloydsPharmacy in the UK

30 January 23

Quarterly Activities Report & Appendix 4C

×

Quarterly Activities Report & Appendix 4C

30 August 16

Starpharma Highlights of FY2016 Presentation

×

Starpharma Highlights of FY2016 Presentation

29 September 23

Ceasing to be a substantial holder

×

Ceasing to be a substantial holder

29 September 08

Annual Report to shareholders

×

Annual Report to shareholders

29 October 21

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

29 November 23

AGM Chairman's address and CEO presentation

×

AGM Chairman's address and CEO presentation

29 November 23

AGM Results

×

AGM Results

29 November 22

AGM Chairman address and CEO presentation

×

AGM Chairman address and CEO presentation

29 November 22

AGM Results

×

AGM Results

29 November 18

AGM - Chairman address and CEO presentation

×

AGM - Chairman address and CEO presentation

29 November 17

AGM - Chairman address and CEO presentation

×

AGM - Chairman address and CEO presentation

29 November 16

AGM - Chairman address and CEO presentation

×

AGM - Chairman address and CEO presentation

29 May 19

Starpharma presents at UBS Healthcare Conference

×

Starpharma presents at UBS Healthcare Conference

SPL Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.05 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock -26.1 20.1 3.8 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.04 -0.03 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -25.2 9.2 4.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -2.5 -4.6 -11.2 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.15 0.12 0.08 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.15 0.12 0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 82.5 -22.8 -28.4 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 397 407 409 Lock Lock Lock
Basic m Lock Lock Lock Lock 397 407 409 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 2 5 3 Lock Lock Lock
     Growth % Lock Lock Lock Lock -70.2 160.4 -37.2 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 29 26 26 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 1 2 1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -87.3 253.3 -35.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock 30.0 40.7 41.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 70 59 58 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -28 -23 -23 Lock Lock Lock
     Growth % Lock Lock Lock Lock -35.2 17.7 -2.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,542.5 -487.3 -798.9 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -29 -24 -25 Lock Lock Lock
     Growth % Lock Lock Lock Lock -33.8 16.7 -3.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,594.5 -510.4 -839.5 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -27 -23 -23 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -7 -7 -8 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -20 -16 -16 Lock Lock Lock
     Growth % Lock Lock Lock Lock -34.4 18.1 3.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,097.4 -345.0 -532.1 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -15 -13 -14 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 1 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -1 -1 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 46 3 -1 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -15 -14 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock -38.1 7.0 -1.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -8.4 -3.0 -4.8 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 60 50 35 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 73 66 52 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 7 3 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -59 -42 -27 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 11 18 17 Lock Lock Lock
Equity $m Lock Lock Lock Lock 62 48 35 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 63 56 38 Lock Lock Lock
     Growth % Lock Lock Lock Lock 94.4 -11.0 -32.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -26.9 -24.4 -30.0 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.7 -33.4 -44.9 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -59.5 -39.8 -49.5 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -41.5 -27.2 -33.5 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -31.2 -22.2 -29.0 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.1 1.8 1.1 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -95.2 -86.2 -77.3 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 6.8 5.9 3.3 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 6.6 5.7 3.1 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 85.5 82.3 74.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -142.0 -128.6 -93.5 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.2 0.6 0.4 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.1 1.2 0.6 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 373.2 144.4 225.1 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.1 0.1 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -1,500.6 -500.1 -791.7 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -36.8 -35.4 -44.7 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -26.9 -24.4 -30.0 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.2 1.4 1.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -31.7 -33.4 -44.9 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -31.7 -33.4 -44.9 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 321.2 298.8 595.1 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 1,474.4 634.4 997.9 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 1,795.6 933.2 1,593.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 815.5 633.9 1,465.9 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 980.2 299.3 127.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.60%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

-0.20%

3 Month Change

-1.00%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

SPL Shortsell

Frequently Asked Questions

The current share price of Starpharma Holdings Limited (SPL:ASX) is AU$0.14.
The 52-week high share price for Starpharma Holdings Limited (SPL:ASX) is AU$0.70.
The 52-week low share price for Starpharma Holdings Limited (SPL:ASX)? is AU$0.12.
Starpharma Holdings Limited (SPL:ASX) does not pay a dividend.
Starpharma Holdings Limited (SPL:ASX) does not pay a dividend.
Starpharma Holdings Limited (SPL:ASX) has a franking level of 0%.
Starpharma Holdings Limited (SPL:ASX) is classified in the Healthcare.
The current P/E ratio for Starpharma Holdings Limited (SPL:ASX) is .